Advertisement

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Presenter: Deepak L. Bhatt

March 30, 2020

REGISTER for free or LOG IN to view this content

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Clinical Cardiology

Prevention

Clinical Pharma

Lipids

Coronary

CAD Pharma

ACC 2020

Icosapent ethyl

EPA

Vascepa

Amarin

Up Next

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

Presenter: Dirk J. Blom

March 30, 2020

More slides +

Effect of Smoking on Outcomes of Primary PCI in Patients With STEMI

April 15, 2020

Incidence, Presentation, and Causes of 30-Day Readmission After Hospitalization With SCAD

April 20, 2020

Country